Leukemia Therapeutics Market Share

Global Leukemia Therapeutics Market Overview

The Leukemia Therapeutics Market Size was valued at USD 16.21 billion in 2022 and is projected to grow from USD 17.22 Billion in 2023 to USD 30.12 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.34% during the forecast period (2023 - 2032). 

Leukemia Therapeutics Market Trends

The market will have high growth in the coming years if the market grows at the same pace. Cancer is a disease of genes caused by the uncontrolled growth of the cells in the body. The affected cells can further spread into another body site from that part through the blood and lymph system. It is known as blood cancer which commonly can happen to adults or children. Several types of leukemia are there, and leukemia therapeutics are used to treat them. The factors that improve the market are the rise of the older population, lifestyle changes, and others are some of the major causes of the market growth. However, the constraint that also hampers the growth pace is the high cost needed to develop new therapeutics. It makes an individual weak and loses the ability to fight any infection. The awareness among people regarding cancer disease and the sudden availability of detection and diagnosis will create more opportunities for the market. Common symptoms of this disease are fatigue, weight loss, frequent infections, easy bleeding or bruising, and some others.

Leukemia Therapeutics Market Segment Insights

The global leukemia therapeutics market has been segmented into type, applications, and region.

Leukemia Therapeutics Type Insights

Based on type, market is segmented into chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The chemotherapy segment is expected to account for the largest share segment of the market. Chemotherapy segment further sub segmented into alkylating agents, antimetabolites, antitumor antibiotics, and others.

Leukemia Therapeutics Application Insights

Based on applications, market is segmented into acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and others.

Leukemia Therapeutics Regional Insights

The market segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas further segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The leukemia therapeutics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa segmented into the Middle East and Africa.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global leukemia therapeutics market owing to a well-established player, innovative therapies to drive the market for leukemia, increase prevalence of leukemia, and increasing older population.

Europe is expected to hold the second largest position in the global market. The market growth in this region is attributed to increase prevalence of leukemia.

The market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region.

The Middle East & Africa has the least share of the leukemia therapeutics market.

Leukemia Therapeutics Market Top Key Players

• Eisai Co., Ltd (Japan)


• Novartis AG (Switzerland)


• Pfizer Inc. (US)


• GlaxoSmithKline plc (UK)


• Bristol-Myers Squibb Company (US)


• Hoffmann-La Roche AG (Switzerland)


• Sanofi S.A. (France)


• Teva Pharmaceutical Industries Ltd (Israel)


• Amgen Inc (US)


• Takeda Pharmaceutical Company Ltd (Japan)

Recent Development

November 2023: Pfizer announced that its new breast cancer drug, palbociclib, has been approved by the FDA for the treatment of patients with HER2-positive metastatic breast cancer. Palbociclib is a CDK4/6 inhibitor that works by blocking the growth and spread of cancer cells.Merck announced that its new breast cancer drug, pembrolizumab, has been approved by the FDA for the treatment of patients with triple-negative breast cancer (TNBC). Pembrolizumab is an immunotherapy drug that works by boosting the body's immune system to fight cancer cells. Roche announced that its new breast cancer drug, tucatinib, has been approved by the FDA for the treatment of patients with HER2-positive advanced or metastatic breast cancer. Tucatinib is a TKI that works by blocking the HER2 protein, which is involved in the growth and spread of cancer cells.

October 2023: A new study published in the journal Nature Cancer finds that a combination of three drugs, including a PARP inhibitor, a CDK4/6 inhibitor, and a hormone therapy drug, is effective in shrinking tumors and prolonging survival in patients with advanced breast cancer.Another study published in the journal Cancer Discovery finds that a new AI-powered algorithm is able to predict the risk of breast cancer recurrence more accurately than traditional methods. The algorithm takes into account a variety of factors, including the patient's tumor characteristics, medical history, and lifestyle.

September 2023: The American Cancer Society released its annual report on cancer statistics, which finds that the breast cancer death rate has decreased by 43% since 1990. The report also finds that the five-year survival rate for breast cancer is now 91%.The National Cancer Institute awarded a grant to a team of researchers at Harvard University to develop a new type of breast cancer vaccine. The vaccine is designed to target a specific protein that is found on the surface of breast cancer cells.

May 2022: BeiGene is a worldwide science-driven biotechnology company that focuses on developing innovative and affordable medicines to improve treatment. It outcomes and access for patients worldwide. The company recently announced that the China National Medical Products Administration (NMPA) had granted conditional approval of BLINCYTO® for injection for the treatment of pediatric patients with relapsed or refractory (R/R) CD19-positive B-cell precursor acute lymphoblastic leukemia. The NMPA gave conditional approval for adult patients in this indication in December 2020.

April 2022: Curis, Inc., a biotechnology company, focuses on developing innovative therapeutics to treat cancer. 

Intended Audience

• Leukemia Therapeutics Manufacturers and Vendors


• Research Organization


• Various Research and Consulting Firms


• Cancer Organization and Association

Leukemia Therapeutics Market Segmentation

Leukemia Therapeutics Treatment Type Outlook

• Chemotherapy




• Alkylating Agents


• Antimetabolites


• Antitumor Antibiotics


• Others




• Biological Therapy


• Targeted Therapy


• Radiation Therapy


• Stem Cell Transplant


• Others

Leukemia Therapeutics Application Outlook

• Acute Lymphocytic Leukemia


• Acute Myelogenous Leukemia


• Chronic Lymphocytic Leukemia


• Chronic Myelogenous Leukemia


• Others

Leukemia Therapeutics Region Outlook

• Americas




• North America




• US


• Canada




• Latin America




• Europe




• Western Europe




• Germany


• France


• Italy


• Spain


• UK


• Rest of Western Europe




• Eastern Europe




• Asia-Pacific




• Japan


• China


• India


• Australia


• South Korea


• Rest of Asia-Pacific




• The Middle East & Africa




• Middle East


• Africa